SEC61G Promotes Cervical Cancer Proliferation by Activating MAPK Signaling Pathway

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Sep 12

PMID 36092956

Authors

Yangyang Fan

Ying Wang

Feifei Liu

Haili Wang

Qiumin Li

Affiliations

Soon will be listed here.

Abstract

Objective: The abnormal expression of SEC61G plays an important role in the development of various tumors. This study explored the effects of SEC61G on MAPK signaling pathway and proliferation of cervical cancer (CC) cells.

Methods: shRNA was used to inhibit the expression of SEC61G and EdU to observe its effect on the proliferation of CC cell SiHa. The effect of SEC61G on invasion was evaluated by Transwell assay. TCGA database was used to analyze the influence of high or low SEC61G expression level on the overall survival of CC patients. Western blot was used to detect the expressions of SEC61G, p-RAF1, Raf1, p-MEK1/2, MEK1/2, and p-ERK1/2 in cells. SiHa cells overexpressing SEC61G (SiHa-SEC61G) and control group (SiHa-mock) were subcutaneously implanted in nude mice. The tumor growth curve was measured at the specified time points between SiHa-SEC61G and SiHa-mock. The inhibitory effect of gefitinib on SEC61G was further evaluated.

Results: In patients with CC, high SEC61G expression predicted poor prognosis. Silencing SEC61G inhibited proliferation and invasion of CC cells in vitro. Overexpression of SEC61G can promote the proliferation and invasion of CC cells in vitro. Meanwhile, overexpression of SEC61G promoted the proliferation of CC xenografts. Knocking down SEC61G can inhibit MAPK signaling pathway. Gefitinib can inhibit CC proliferation and tumor growth by SEC61G.

Conclusion: SEC61G is highly expressed in CC and has poor prognosis. Inhibition of SEC61G expression can effectively inhibit the growth and proliferation of human CC cells. The mechanism may be related to the inhibition of MAPK signaling pathway.

Citing Articles

An original aneuploidy-related gene model for predicting lung adenocarcinoma survival and guiding therapy.

Zhang Y, Li D Sci Rep. 2024; 14(1):8135.

PMID: 38584220 PMC: 10999435. DOI: 10.1038/s41598-024-58020-y.

SEC61 translocon subunit gamma enhances low-dose cisplatin-induced cancer-stem cell properties of head and neck squamous cell carcinoma via enhancing Ca-mediated autophagy.

Bu X, Zhang J, Sun H, Wang W, Ma X, Sun L J Dent Sci. 2023; 18(4):1685-1692.

PMID: 37799908 PMC: 10547946. DOI: 10.1016/j.jds.2023.01.024.

References

Wen-Sheng W . Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Cancer Lett. 2005; 239(1):27-35. DOI: 10.1016/j.canlet.2005.07.034. View

Vu M, Yu J, Awolude O, Chuang L . Cervical cancer worldwide. Curr Probl Cancer. 2018; 42(5):457-465. DOI: 10.1016/j.currproblcancer.2018.06.003. View

Liu B, Liu J, Liao Y, Jin C, Zhang Z, Zhao J . Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma. Med Sci Monit. 2019; 25:3624-3635. PMC: 6536036. DOI: 10.12659/MSM.916648. View

Fang J, Richardson B . The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005; 6(5):322-7. DOI: 10.1016/S1470-2045(05)70168-6. View

Cohen P, Jhingran A, Oaknin A, Denny L . Cervical cancer. Lancet. 2019; 393(10167):169-182. DOI: 10.1016/S0140-6736(18)32470-X. View

Gogala M, Becker T, Beatrix B, Armache J, Barrio-Garcia C, Berninghausen O . Structures of the Sec61 complex engaged in nascent peptide translocation or membrane insertion. Nature. 2014; 506(7486):107-10. DOI: 10.1038/nature12950. View

Rezatabar S, Karimian A, Rameshknia V, Parsian H, Majidinia M, Kopi T . RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression. J Cell Physiol. 2019; 234(9):14951-14965. DOI: 10.1002/jcp.28334. View

Peluso I, Yarla N, Ambra R, Pastore G, Perry G . MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. Semin Cancer Biol. 2017; 56:185-195. DOI: 10.1016/j.semcancer.2017.09.002. View

Lei J, Ploner A, Elfstrom K, Wang J, Roth A, Fang F . HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020; 383(14):1340-1348. DOI: 10.1056/NEJMoa1917338. View

10.

Sheng W, Shi X, Lin Y, Tang J, Jia C, Cao R . Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. J Exp Clin Cancer Res. 2020; 39(1):16. PMC: 6967093. DOI: 10.1186/s13046-020-1521-4. View

11.

Johnson C, James D, Marzan A, Armaos M . Cervical Cancer: An Overview of Pathophysiology and Management. Semin Oncol Nurs. 2019; 35(2):166-174. DOI: 10.1016/j.soncn.2019.02.003. View

12.

Balasubramaniam S, Balakrishnan V, Oon C, Kaur G . Key Molecular Events in Cervical Cancer Development. Medicina (Kaunas). 2019; 55(7). PMC: 6681523. DOI: 10.3390/medicina55070384. View

13.

Voorhees R, Fernandez I, Scheres S, Hegde R . Structure of the mammalian ribosome-Sec61 complex to 3.4 Å resolution. Cell. 2014; 157(7):1632-43. PMC: 4081569. DOI: 10.1016/j.cell.2014.05.024. View

14.

Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L . A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers (Basel). 2019; 11(10). PMC: 6827047. DOI: 10.3390/cancers11101618. View

15.

Chetram M, Hinton C . PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res. 2012; 32(4):190-5. PMC: 3503241. DOI: 10.3109/10799893.2012.695798. View

16.

Bradham C, McClay D . p38 MAPK in development and cancer. Cell Cycle. 2006; 5(8):824-8. DOI: 10.4161/cc.5.8.2685. View

17.

Lee S, Rauch J, Kolch W . Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. Int J Mol Sci. 2020; 21(3). PMC: 7037308. DOI: 10.3390/ijms21031102. View

18.

de Leeuw R, McNair C, Schiewer M, Neupane N, Brand L, Augello M . MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clin Cancer Res. 2018; 24(17):4201-4214. PMC: 6125187. DOI: 10.1158/1078-0432.CCR-18-0410. View

19.

Liu F, Yang X, Geng M, Huang M . Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018; 8(4):552-562. PMC: 6089851. DOI: 10.1016/j.apsb.2018.01.008. View

20.

Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2019; 8(2):e191-e203. PMC: 7025157. DOI: 10.1016/S2214-109X(19)30482-6. View